Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report report published on Tuesday. The brokerage issued a hold rating on the stock.

A number of other brokerages have also recently weighed in on EKSO. HC Wainwright dropped their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital dropped their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Price Performance

Ekso Bionics stock opened at $0.71 on Tuesday. Ekso Bionics has a one year low of $0.71 and a one year high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The business has a fifty day moving average of $1.02 and a two-hundred day moving average of $1.10. The company has a market cap of $15.55 million, a P/E ratio of -1.09 and a beta of 1.47.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter in the prior year, the business earned ($0.24) EPS. As a group, analysts predict that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC grew its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.